samedan logo
 
 
 
spacer
home > ebr > autumn 2020 > medical communications transformed
PUBLICATIONS
European Biopharmaceutical Review

Medical Communications Transformed

Like other business sectors, medical health communications or ‘medhealth comms’ has been completely upended by the COVID-19 pandemic. This £13 billion industry has had to adapt to a new reality, and fast, in order to meet the rapidly changing needs of its stakeholders. First let’s take a step back and explain the importance of medhealth comms.

Explaining Medhealth Comms

Simply put, medhealth comms help pharmaceutical developers to better communicate with their stakeholders, including healthcare practitioners, such as doctors, nurses, prescribers, and, of course, patients. A drug company launching a new product will have reams of highly-technical data and reports that are hard to understand. Medhealth comms can help turn these complex data into clear, credible, and effective communications. Alternatively, a national regulator like the National Institute for Health and Care Excellence, which is responsible for providing national guidance and advice to improve health and social care, might publish new guidelines on COVID-19 or a specific treatment. Medhealth comms will help interpret them so healthcare professionals (HCPs) can better understand them. Accurate information and honest opinions help HCPs to make treatment decisions with confidence, leading to better patient outcomes.

Traditionally, this has been done in a variety of ways, by creating impactful collaterals such as interactive publication tools, case studies, educational videos, logos, and branding. It’s also done by organising seminars and conferences that bring together HCPs, drug companies, and third-party independent experts.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Following a successful career in the pharma industry, Shairose Ebrahim founded imc in 2006 from her home office. The company has gone from strength to strength and today employs over 100 staff across five divisions, with five offices in London, Cambridge, Toronto, Boston, and Cairo, working with some of the world’s biggest pharma companies to deliver better outcomes for patients. Shairose credits healthcare heroes who inspired her to succeed in her career, including Dr Jane Cooke Wright who developed a non-surgical method of fighting tumours, Dr Mae Jemison who was appointed by NASA to conduct experiments in space, and Dr Patricia Bath who created an entirely new discipline of ophthalmology focused on public health.
spacer
Shairose Ebrahim
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Volga-Dnepr’s Cargo Supermarket Spins Healthcare Logistics Across Transatlantic Through A Collaborative Approach

Volga-Dnepr Group continues to support the life-saving uninterrupted supply chains through its dedicated services and Cargo Supermarket offering in partnership with DHL Global Forwarding LS&H sector experts. This time AirBridgeCargo Airlines and CargoLogicAir organized delivery of insulin in a batch of Envirotainer and DoKaSch RAP containers from Milan (Italy) to Chicago (USA).
More info >>

White Papers

Sourcing Commercial Drugs for Clinical Trials: US vs. EU Understanding the Differences

Myoderm

Sourcing commercial drugs for clinical trials is a dynamic process. There are many factors to consider: single source or regional sourcing, strategy, price, supply availability, lead times, and documentation are just a few. In the past, there were fewer clinical trials that required commercial drug sourcing, so demand was not as high. Today, the demand for commercial drugs in clinical trials has greatly increased and, as a result, inventory is tighter, orders are monitored more closely by manufacturers, and lead times have increased. This report highlights the key differences in sourcing from the US and EU.
More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement